Ypsomed has announced a strategic partnership with Swiss contract development and manufacturing organisation ten23 health to advance the commercialisation of the YpsoDose wearable injector.

The YpsoDose patch injector is designed for the subcutaneous self-injection of large-volume doses.

The collaboration aims to provide a fully integrated solution, combining Ypsomed's device platform with ten23 health's capabilities in drug development, filling, and device assembly.

Ypsomed said the integrated offering will include Schott Pharma's ready-to-use cartriQ glass cartridge as the primary drug packaging, Ypsomed's YpsoDose patch injector platform, and ten23 health's services covering formulation and process development, filling, assembly, and quality control testing.

Pharmaceutical customers can get a stringently tested and documented solution, thereby significantly expediting the time to clinic and market, and enabling them to focus on their core initiatives.

ten23 health chief enablement officer Dr Hanns-Christian Mahler said: “Successful drug product by which the drug-device integration is taken into account from the very beginning of its design – where formulation, primary packaging, and medical devices are an equally important part, providing stable, safe, usable and effective medicines to patients.”

The company's proficiency in the clinical and commercial fill and finish of intricate dosage forms, particularly large-volume cartridges for devices, positions it as a key player in meeting the unique requirements to advance the YpsoDose patch injector's commercialisation.

Ypsomed large volume injectors lead Reto Jost said: “Together with ten23 as a strong partner, we offer a comprehensive solution, for our customers to bring their medicines to market as a commercially viable and competitive product in a short time, at a lower cost and with low risks.”

Last month, Ypsomed agreed to sell its pen needle and blood glucose monitoring systems businesses to Medical Technology and Devices (MTD).